CrownBio in $1M new-facility collab with New Iberia Research Center

CrownBio teams up with New Iberia Research Center in establishing a $1 million subsidiary in Louisiana.

Crown Bioscience will invest $1 million into establishment of a pharmaceutical R&D facility in Louisiana at New Iberia Research Center, one of the country’s largest nonhuman primate labs.

The $1 million injection, according to a press release, will create 10 new direct jobs with an average annual wage of $70,000. Local economic development authority estimates that the new center will add an additional 14 indirect jobs.

CrownBio, headquartered in Santa Clara, California, currently has research branches in China, the U.K., San Diego and Indianapolis. The company’s key products are several oncology platforms for use in drug discovery, among them are patient-derived xenograft models and 8,000 viable human tumors the company acquired in 2015 from Molecular Response.

Featured Whitepaper

Accelerate Clinical Operations Across Sponsors, CROs, and Partners

The most advanced life sciences organizations know that digital innovation and multi-platform integrations are essential for enabling product development. New platforms are providing the life sciences industry with an opportunity to improve the efficiency of clinical trials and reduce costs while remaining compliant and reducing risk.

Last March, the company acquired Indianapolis, IN-based PreClinOmics, adding cardiovascular and metabolic diseases preclinical capabilities to its portfolio. It is exactly in these two fields the global CRO intends to advance with this new project.

As CrownBio’s CEO Jean-Pierre Wery said in a statement, the company eyed Louisiana, and NIRC to be specific, because of a growing biomedical science community. “It was important for us to be located at a facility with multiple research capabilities that could harmonize well with the various efficacy and model development studies conducted by CrownBio,” he said.

A subsidiary of the University of Louisiana at Lafayette, the New Iberia Research Center houses over 6,000 nonhuman primates for applied and basic research. The site itself provides contract research services in fields like pharmacodynamics, safety monitoring, dose finding and vaccine development, etc.

The deal utilized the state’s Quality Jobs Program, and was facilitated by the Iberia Industrial Development Foundation, One Acadiana and LED. CrownBio will begin operating at the New Iberia Research Center within this month.

Suggested Articles

Clinical trial firm Phesi’s new report is some grim reading for the life science industry: Studies for new drugs are still suffering.

Tempus fugit: And time especially flies when it comes clinical trials. Covance is teaming up with the suitably named Tempus to clip its wings.

PPD has raised its quarterly guidance after weathering the COVID-19 storm and is immediately making a secondary offering of 38 million shares.